Eli Lilly's Foundayo, a Game-Changing Oral Obesity Treatment, Receives FDA Approval
FDA Approves Foundayo, a Novel Oral Obesity Drug
The U.S. Food and Drug Administration (FDA) has granted final approval for Foundayo (active ingredient: orforglipron), the first oral non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) developed by Eli Lilly and Company (LLY) for the treatment of obesity. This marks a significant advancement in the obesity treatment market, which has primarily relied on injectable medications, by offering a more convenient oral administration option. Foundayo is expected to significantly improve patient adherence to treatment regimens. Unlike existing oral peptide treatments, Foundayo can be taken at any time of day without dietary or fluid restrictions, providing a substantial advantage in terms of patient convenience.
Superior Weight Loss Efficacy Demonstrated in the ATTAIN-1 Phase 3 Clinical Trial
Foundayo has demonstrated both potent weight loss effects and a favorable safety profile in the ATTAIN-1 study, a large, global Phase 3 clinical trial. In the 72-week clinical trial, patients receiving the highest dose of 36mg of Foundayo achieved an average weight loss of 12.4%, a statistically significant difference compared to the 0.9% weight loss observed in the placebo group. Furthermore, 59.6% of the overall treatment group experienced a weight loss of 10% or more, and 39.6% of patients achieved a weight loss of 15% or more, demonstrating strong efficacy as a treatment option for obesity.
Global License Agreement with Chugai Pharmaceutical and Development Journey
The active ingredient in Foundayo, OWL833, is a small molecule compound that Eli Lilly acquired from Chugai Pharmaceutical (4519) of Japan in September 2018 through a global exclusive license agreement. At the time of the agreement, Eli Lilly made an upfront payment of $50 million to Chugai Pharmaceutical and agreed to make future milestone payments and royalty payments based on sales. This strategic investment by Lilly has proven successful, creating a win-win situation for both companies, with the potential for significant financial benefits and royalty income from the commercialization of Foundayo.
Competition for Dominance in the $100 Billion Obesity Treatment Market
The global obesity treatment market is projected to grow rapidly to $100 billion by 2030, making it a key area of focus in the biopharmaceutical industry. Foundayo is a strong pipeline product that is expected to quickly gain market share from existing injectable and peptide-based oral treatments, such as Wegovy and Rybelsus from Novo Nordisk (NVO), and Zepbound from Eli Lilly. With competitors such as Pfizer's (PFE) danuglipron and Roche's (RHHBY) CT-996 still in early stages of clinical development, the rapid market entry of Foundayo is poised to further solidify Eli Lilly's leadership position in the obesity market.
Eli Lilly's approval of Foundayo provides a unique first-mover advantage in the obesity market, which is expected to grow to $100 billion by 2030, as an oral non-peptide treatment. Unlike Novo Nordisk's Rybelsus, which has strict dietary restrictions, Foundayo's unrestricted administration will significantly improve patient compliance and market share. The 12.4% weight loss observed in the ATTAIN-1 Phase 3 trial with the highest dose of 36mg demonstrates its potential as a strong alternative to existing injectable treatments. The $50 million upfront payment and milestone structure paid to Chugai Pharmaceutical is considered a successful example of open innovation in drug development and is positively impacting the stock prices of both companies. With Pfizer's danuglipron still in Phase 2 clinical trials, the market launch of Foundayo will solidify Eli Lilly's long-term dominance in the obesity market.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/drugs/information-consumers-and-patients-drugs/find-information-about-drug